Innovative pharmacologic approaches to cardiopulmonary resuscitation

Journal of Clinical Pharmacology

Volumn 38, Issue 9, 1998, Pages 765-772

  Frishman, William H ^a,e   Vahdat, Shadi ^b   Bhatta, Sanjeev ^c,d  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ST BARNABAS HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AMINOPHYLLINE; AMIODARONE; ATROPINE; BRETYLIUM; CATECHOLAMINE; ENCAINIDE; ENDOTHELIN; FLECAINIDE; HYPERTENSIVE FACTOR; LEVOTHYROXINE SODIUM; LIDOCAINE; LIOTHYRONINE; METHOXAMINE; MORACIZINE; NITRIC OXIDE; PHENYLEPHRINE; PROCAINAMIDE; SOTALOL; THEOPHYLLINE; THYROID HORMONE; THYROXINE; VASOPRESSIN; VASOPRESSIN V1 RECEPTOR;

BLOOD VESSEL REACTIVITY; BRADYCARDIA; CARDIOVASCULAR PERFORMANCE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HEART ARREST; HEART MUSCLE POTENTIAL; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; ORGAN PERFUSION; PRACTICE GUIDELINE; RESUSCITATION; REVIEW; SURVIVAL RATE; TORSADE DES POINTES; TREATMENT FAILURE;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOPULMONARY RESUSCITATION; ENDOTHELIN-1; HEART ARREST; HUMANS; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 0031657215     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Tucker KJ, Larson JL, Idris A, Curtis AB: Advanced cardiac life support: update on recent guidelines and a look at the future. Clin Cardiol 1995;18:497-504.
2. American Heart Association Emergency Cardiac Care Committee and Subcommittees: Guidelines for cardiopulmonary resuscitation and emergency cardiac care. III. Adult advanced cardiac life support. JAMA 1992;268:2199-2241.
3. Ornato JP, Gonzalez ER, Jaffe AS: Use of cardiovascular drugs during cardiopulmonary resuscitation. In, Messerli FH (ed.): Cardiovascular Drug Therapy. Second edition. Philadelphia: WB Saunders, 1996;206-224.
4. Michael JR, Guerci AD, Koehler RC, Shi AY, Tsitlik J, Chandra N, et al: Mechanism by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 1984;69:822-835.
5. Midei MG, Sugiura S, Maughan WL, Sagawa K, Weisfeldt ML, Guerci AD: Preservation of ventricular function by treatment of ventricular fibrillation with phenylephrine. J Am Coll Cardiol 1990;16:489-494.
6. Woodhouse SP, Cox S, Boyd P, Case C, Weber M: High dose and standard dose adrenaline do not alter survival compared with placebo in cardiac arrest. Resuscitation 1995;30:243-249.
7. Stiell IG, Hebert PC, Weitzman BN, Wells GA, Raman S, Stark RM, et al: High-dose epinephrine in adult cardiac arrest. N Engl J Med 1992;327:1045-1050.
8. Brown CG, Martin DR, Pepe PE, Steuven H, Cummins RO, Gonzalez E, Jastremski M: A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital: the Multicenter High-Dose Epinephrine Study Group. N Engl J Med 1992;327:1051-1055.
9. Schleien CL, Koehler RC, Gervais H, Berkowitz ID, Dean JM, Michael JR, et al: Organ blood flow and somatosensory-evoked potentials during and after cardiopulmonary resuscitation with epinephrine or phenylephrine. Circulation 1989;79: 1332-1342.
10. Brown CG, Davis EA, Werman HA, Hamlin RL: Methoxamine versus epinephrine on regional cerebral blood flow during cardiopulmonary resuscitation. Crit Care Med 1987;15:682-686.
11. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M: Stress hormone response during and after cardiac arrest and cardiopulmonary resuscitation. Anesthesiology 1992;77:662-668.
12. Chugh SS, Luire KG, Lindner KH: Pressor with promise: using vasopressin in cardiopulmonary arrest. Circulation 1977; 96:2453-2454.
13. Burbach H, Adan RA, Lolait SJ, van Leeuwen FW, Mezey E, Palkovits M, Barberis C: Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell Mol Neurobiol 1995;15:573-595.
14. Cartheuser CF, Komarek J: Effects of vasopressin on the circulation, myocardial dynamics, and left ventricular oxygen consumption in the anaesthetized dog. Basic Res Cardiol 1980;75: 668-682.
15. Frishman WH, Mayerson AB: Vasopressin and vasopressin receptor antagonists in cardiovascular disease. In, Frishman WH, Sonnenblick EH (eds.): Cardiovascular Pharmacotherapeutics. New York: McGraw Hill, 1997;769-785.
16. Lindner KH, Prengel AW, Pfenninger EG, Lindner IM, Strohmenger HU, Georgieff M, Lurie KG: Vasopression improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 1995;91:215-221.
17. Lindner KH, Brinkmann A, Pfenninger EG, Lurie KG, Goertz A, Lindner IM: Effect of vasopressin on hemodynamic variables, organ blood flow, and acid-base status in a pig model of cardiopulmonary resuscitation. Anesth Analg 1993;77:427-435.
18. Fox AW: Vascular vasopressin receptors. Gen Pharmacol 1988;19:639-647.
19. Prengel AW, Lindner KH, Keller A: Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 1996;27:1241-1248.
20. Suzuki Y, Satoh S, Oyama H, Takayasu M, Shibuya M: Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke 1993;24:1049-1054.
21. Faraci FM, Heistad DD: Regulation of cerebral blood vessels by humoral and endothelium dependent mechanisms. Hypertension 1991;17:917-922.
22. Foreman BW, Dai XZ, Bache RJ: Vasoconstriction of canine coronary collateral vessels with vasopressin limits blood flow to collateral-dependent myocardium during exercise. Circ Res 1991; 69:657-664.
23. Rapps JA, Jones AW, Sturek M, Magliola L, Parker JL: Mechanisms of altered contractile responses to vasopressin and endothelin in canine coronary collateral arteries. Circulation 1997;95: 231-239.
24. Prengel AW, Lindner KH, Keller A, Lurie KG: Cardiovascular function during the post-resuscitation phase after cardiac arrest in pigs: a comparison of epinephrine versus vasopressin. Crit Care Med 1996;24:2014-2019.
25. Lindner KH, Prengel AW, Brinkman A, Strohmenger HU, Lindner IM, Lurie KG: Vasopressin administration in refractory cardiac arrest. Ann Intern Med 1996;124:1061-1064.
26. Lindner KH, Dirks B, Strohmenger HU, Prengel AW, Lindner IM, Lurie KG: Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997;349:535-537.
27. Lazzara R: From first class to third class: recent upheaval in antiarrhythmic therapy; lessons from clinical trials. Am J Cardiol 1996;78:28-33.
28. Grace AA, Camm AJ: Quinidine. New Engl J Med 1998;338: 35-45.
29. Rang HP, Dale MM, Ritter JM, Gardner P: The heart. In, Rang HP, Dale MM, Ritter JM, Gardner P (eds.): Pharmacology. New York: Churchill Livingstone, 1995;269-300.
30. Zaritsky A: Resuscitation pharmacology. In, Chernow B (ed.): The Pharmacologic Approach to the Critically Ill Patient. Baltimore: Williams & Wilkins, 1994;233-246.
31. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S: Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA 1988;260:1910-1916.
32. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al, and the CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788.
33. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
34. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pitt B, et al, and the SWORD Investigators: Preliminary mortality results from the survival with oral d-sotalol (SWORD) trial (abstract). J Am Coll Cardiol 1995;15A(special issue).
35. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarctions with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-1718.
36. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, et al: Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled pilot study. J Am Coll Cardiol 1992;20:1056-1062.
37. Kim SG: Evaluation of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators. Am Heart J 1995;130:1144-1150.
38. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997;96:2823-2829.
39. Chow MSS: Intravenous amiodarone: pharmacology, pharmacokinetics and clinical use. Ann Pharmacother 1996;30:637-643.
40. Desai AD, Chun S, Sung RJ: The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997;127:294-303.
41. Cote P, Bourassa MG, Delaye J, Janin A, Froment R, David P: Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease. Circulation 1979;59:1165-1172.
42. Kosinski EJ, Albin JB, Young E, Lewis SM, LeLand OS: Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol 1984;4:565-570.
43. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, et al, for the Intravenous Amiodarone Multicenter Investigators Group: Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995;92:3264-3272.
44. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, et al, for the Intravenous Amiodarone Multicenter Investigators Group: Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation 1995;92:3255-3263.
45. Hohnloser SH, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects a review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-535.
46. Iseri LT, Humphrey SB, Siner EJ: Prehospital brady-asystolic cardiac arrest. Ann Intern Med 1978;88:741-745.
47. Myerburg RJ, Conde CA, Sung RJ, Mayorga-Cortes A, Mallon SM, Sheps DS, et al: Clinical, electrophysiologic and hemodynamic profile of patients resuscitated from prehospital cardiac arrest. Am J Med 1980;68:568-576.
48. Eisenberg MS, Hadas E, Nuri I, Applebaum D, Roth A, Litwin PE, et al: Sudden cardiac arrest in Israel: factors associated with successful resuscitation. Am J Emerg Med 1988;6: 319-323.
49. Stratton SJ, Niemann JT: The effects of adding links to the chain of survival for out of hospital cardiac arrest: a contrast of outcomes in 1975 and 1995 at a single institution. Acad Emerg Med 1997;4:342-530.
50. Ornato JP, Peberdy MA: The mystery of bradyasystole during cardiac arrest. Ann Emerg Med 1996;27:576-587.
51. Bardenheuer H, Schrader J: Supply-to-demand ratio for oxygen determines formation of adenosine by the heart. Am J Physiol 1986;250:H173-H180.
52. Berne RM: The role of adenosine in the regulation of coronary blood flow. Circ Res 1980;47:807-813.
53. Belardinelli L, Isenberg G: Actions of adenosine and isoproterenol on isolated mammalian ventricular myocytes. Circ Res 1983;53:287-297.
54. Somer BG, Frishman WH: Adenosine and its pharmacologic manipulation in cardiovascular disease. In, Frishman WH, Sonnenblick EH (eds.): Cardiovascular Pharmacotherapeutics. New York: McGraw Hill, 1997;703-726.
55. Belardinelli L, Linden J, Berne RM: The cardiac effects of adenosine. Prog Cardiovasc Dis 1989;32:73-97.
56. Lerman BB, Engelstein ED: Metabolic determinants of defibrillation: role of adenosine. Circulation 1995;91:838-844.
57. Wesley RC Jr., Belardinelli L: Role of endogenous adenosine in postdefibrillation bradyarrhythmia and hemodynamic depression. Circulation 1989;80:128-137.
58. Olah ME, Stiles GL: Adenosine receptors. Ann Rev Physiol 1992;54:211-225.
59. Littman L, Ashline PT, Hayes WJ, Kempler P, Raymond RM, Norton HJ, et al: Aminophylline fails to improve the outcome of cardiopulmonary resuscitation from prolonged ventricular fibrillation: a placebo-controlled, randomized, blinded experimental study. J Am Coll Cardiol 1994;23:1708-1714.
60. Wesley RC Jr., Lerman BB, DiMarco JP, Berne RM: Mechanism of atropine-resistant atrio-ventricular block during inferior myocardial infarction: possible role of adenosine. J Am Coll Cardiol 1986;8:1232-1234.
61. Feigl D Ashkenazy J, Kishon Y: Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol 1984;4:35-38.
62. Viskin S, Belhassen B, Roth A, Reicher M, Averbuch M, Sheps D, et al: Aminophylline for bradyasystolic cardiac arrest refractory to atropine and epinephrine. Ann Intern Med 1993; 118:279-281.
63. Wortsman J, Premachandra BN, Chopra IJ, Murphy JE: Hypothyroxinemia in cardiac arrest. Arch Intern Med 1987;147:245-248.
64. Facktor MA, Mayor GH, Machreiner RF, D'Alecy LG: Thyroid hormone loss and replacement during resuscitation from cardiac arrest in dogs. Resuscitation 1993;26:141-162.
65. Whitesall SE, Mayor GH, Nachreiner RF, Zwemer CF, D'Alecy LG: Acute administration of T3 or rT3 failed to improve outcome following resuscitation from cardiac arrest in dogs. Resuscitation 1996;33:53-62.
66. Longstreth WT Jr., Manowitz NR, DeGroot LJ, Siscovich DS, Mayor GH, Copass MK, et al: Plasma thyroid hormone profiles immediately following out-of-hospital cardiac arrest. Thyroid 1996;6:649-653.
67. Tamirisa P, Frishman WH, Kumar A: Endothelin and endothelin antagonism. In, Frishman WH, Sonnenblick EH (eds.): Cardiovascular Pharmacotherapeutics. New York: McGraw Hill, 1997;689-701.
68. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
69. Haynes WG, Hamer DW, Robertson CE, Webb DJ: Plasma endothelin following cardiac arrest: differences between survivors and non-survivors. Resuscitation 1994;27:117-122.
70. Takasu A, Yagi K, Okada Y: Role of endothelin-1 in the failure of cerebral circulation after complete global cerebral ischemia. Resuscitation 1995;30:69-73.